Brazilian Journal of Medical and Biological Research

Brazilian Journal of Medical and Biological Research is an electronic-only, open-access title owned by the Associação Brasileira de Divulgação Científica and devoted to laboratory and clinical work across the biomedical sciences.《巴西医学与生物学研究杂志》由 Associação Brasileira de Divulgação Científica 持有，是纯电子出版的开放获取期刊，刊载生物医学领域的实验室研究与临床研究。

Its editorial office sits at the Ribeirão Preto medical school of the University of São Paulo, and the full text has been free on the SciELO platform since 1997.编辑部设于圣保罗大学里贝朗普雷图医学院，1997 年起全文在 SciELO 平台免费开放。

The 2025 Journal Impact Factor stands at 1.9 with a five-year figure of 2.1, a second-quartile place in biology, and 94.44 percent of output published gold.2025 年影响因子为 1.9，五年影响因子 2.1，在生物学类目居第二四分位，当年产出有 94.44% 以金色开放获取发表。

Scope

• The stated aim is to publish original and innovative research that contributes significantly to knowledge in the medical and biological sciences, admitting clinical studies, experimental work, new techniques, reviews and ethical debate.刊物声明的宗旨是发表对医学与生物学知识有实质贡献的原创研究，临床研究、实验工作与新技术均在收稿范围之内，综述和科研伦理讨论同样接纳。
• Physiology holds a founding place, given the society origins of the title, and work on cardiovascular, respiratory, renal and endocrine function appears beside exercise and environmental physiology.生理学自创刊起就占据核心位置，这与刊物的学会渊源相合，心血管、呼吸与肾脏功能的研究常与运动生理并列出现。
• Pharmacology follows the same lineage, with drug action, pharmacokinetics, cardiovascular agents and experimental therapeutics forming a steady stream of contributions from Brazilian laboratories and their collaborators abroad.药理学承接同一渊源，药物作用、药代动力学与实验治疗构成本国实验室持续供稿的方向，境外合作者也常在此发表。
• Neuroscience and behaviour form one of the eight section headings, covering behavioural pharmacology, neurochemistry, pain, epilepsy and the neurobiology of psychiatric and neurodegenerative conditions.神经科学与行为是八个分栏之一，行为药理学、神经化学与疼痛机制都在其中，癫痫以及精神与神经退行性疾病的神经生物学同样常见。
• Immunology and inflammation run through much of the back file, from innate signalling and macrophage biology to vaccine studies, Chagas disease, leishmaniasis and other neglected infections of the region.免疫与炎症贯穿大部分存卷，从先天免疫信号与巨噬细胞生物学，到疫苗研究、恰加斯病与利什曼病等区域性被忽视感染。
• Cell biology covers the cytoskeleton, membrane traffic, autophagy, cell death and the tumour microenvironment, with imaging and functional assays reported in enough detail for replication elsewhere.细胞生物学涉及细胞骨架、膜运输与自噬，细胞死亡和肿瘤微环境也在范围内，成像与功能实验的报告细到可在他处复现。
• Biochemistry and molecular biology carry enzymology, protein structure, gene regulation and the molecular genetics of inherited disease, a section that has supplied some of the most cited papers in the archive.生物化学与分子生物学承担酶学、蛋白质结构与基因调控，遗传病的分子遗传学同样归入此栏，该栏贡献了存卷中被引最多的若干论文。
• Biological pathogenic agents, the section name the journal actually uses, gathers bacteriology, virology, parasitology and fungal infection, with host-pathogen interaction favoured over descriptive microbiology.刊物把微生物与感染归入 Biological Pathogenic Agents 一栏，内容涉及细菌、病毒与寄生虫，重点落在宿主与病原体的相互作用上。
• Clinical investigation takes patient-based studies, including cardiology, haematology, nephrology, psychiatry and infectious disease cohorts, and expects trials to be registered before submission.临床研究栏接收以患者为对象的工作，心脏病学、血液学与精神病学的队列研究都在其中，投稿前须完成试验注册。
• Population work sits at the laboratory edge of public health, with seroprevalence surveys, diagnostic accuracy studies and spatial analyses of outbreaks appearing beside bench research in the same issues.人群研究处在公共卫生的实验室一侧，血清阳性率调查、诊断准确性评价与疫情空间分析常与台面研究同期刊出。
• Seven manuscript categories are open, among them full-length research papers, short communications, concepts and comments, case reports, critical reviews, overviews and systematic reviews with meta-analysis.可投的稿件分七类，全文研究与短通讯是常规形制，观点评论、病例报告与综述各有篇幅上限，系统评价与荟萃分析单列一类。
• Length limits follow the category, with forty references for full papers, twenty for short communications and case reports, and ninety for reviews, systematic reviews and overviews.篇幅上限按栏目设定，全文研究限 40 条参考文献，短通讯与病例报告限 20 条，综述、系统评价与概述可到 90 条。
• Several classes of paper are refused outright, among them preliminary reports, purely computational work, veterinary medicine, toxicology, animal pharmacokinetics and cross-cultural validation of instruments.若干类别明确不予受理，初步结果与缺乏实验的纯计算工作不在考虑之列，兽医研究被排除，毒理学与动物药代动力学同样如此，量表跨文化验证也不接收。
• Natural-product submissions face extra conditions, since crude extracts must be separated into active fractions, a mechanism must be probed, and plant material must be identified with a voucher specimen deposited.天然产物研究另加条件，粗提物须分离到活性组分，作用机制须有实验探查，植物材料须经专家鉴定并留存凭证标本。

History

• The present title began in 1981 with volume 14, a numbering that continues a series launched in 1968 as Revista brasileira de pesquisas médicas e biológicas.现名自 1981 年第 14 卷启用，卷号承接 1968 年创刊的旧题系列（Revista brasileira de pesquisas médicas e biológicas）。
• ABDC, the Associação Brasileira de Divulgação Científica, founded and still owns the journal, a non-profit federation of eight Brazilian scientific societies rather than a commercial publisher.刊物由 ABDC 创办并持有，全称为 Associação Brasileira de Divulgação Científica，这是一家由八家巴西学会组成的非营利联合会，并非商业出版集团。
• Those societies span biophysics, physiology, pharmacology and experimental therapeutics, immunology, neuroscience and behaviour, biochemistry and cell biology, fixing the disciplinary map at foundation.八家学会分属生物物理与生理学，药理学与实验治疗另成一系，免疫学与神经科学各有代表，刊物的学科版图在创办时即已定型。
• Print issues carried ISSN 0100-879X from 1981 to 1997, when the journal went electronic only and adopted 1414-431X, the number it still uses.1981 年至 1997 年印刷版使用 ISSN 0100-879X，改为纯电子出版后启用 1414-431X，沿用至今。
• Editing has been based at the Ribeirão Preto medical school of the University of São Paulo, in the interior of São Paulo state, rather than in Rio de Janeiro or the capital.编辑部一直设在圣保罗州内陆的圣保罗大学里贝朗普雷图医学院，而不在里约热内卢或联邦首都。
• From 1997 the complete text has lived on the SciELO platform, with a parallel site run by the journal itself, and both have carried the public record for nearly three decades.1997 年起全文迁入 SciELO 平台，刊物另设自有站点，两个入口承担公开存档已近三十年。
• Twelve numbered issues filled every volume from volume 30 in 1997 through volume 54 in 2021, and from 2022 the journal dropped issue numbers for continuous publication.自 1997 年第 30 卷起，直到 2021 年第 54 卷，每卷都编满 12 期，2022 年起取消期号，改为每年一卷、随录随发。
• Recent volumes carry between one hundred and one hundred and twenty items, from 107 in 2022 to 122 in 2024, and volume 59 had passed eighty pieces by October 2026.近年每卷刊出百篇上下，2022 年 107 篇，2024 年 122 篇，2026 年第 59 卷到 10 月已过 80 篇。
• Open access is gold rather than hybrid, articles appear under CC BY, authors keep copyright, and 94.44 percent of 2025 output qualified as gold in the JCR release.开放获取属金色而非混合模式，论文以 CC BY 发布，著作权留在作者手中，2025 年产出有 94.44% 在 JCR 统计中计为金色。
• A publication fee replaced subscription income, 4,000 reais for authors in Brazil and 1,800 dollars for those abroad, charged once a paper is accepted and independent of length.版面费取代订阅收入，巴西作者为 4000 雷亚尔，境外作者为 1800 美元，论文录用后一次性收取，与篇幅无关。
• For some years the enterprise was partly financed by CNPq, the science ministry, CAPES, the education ministry and FAPESP, a mix typical of Brazilian public research funding.有若干年办刊经费部分来自 CNPq、科技部与 CAPES，教育部和 FAPESP 也曾出资，这一组合是巴西公共科研资助的典型样貌。
• Impact factors moved from 2.59 in 2021 to 2.904 in 2022, then 1.9, 1.5 and 1.9 in the three latest releases, with a five-year figure of 2.1.影响因子 2021 年为 2.59，2022 年升至 2.904，此后三次公布依次为 1.9、1.5 与 1.9，五年影响因子 2.1。
• The 2025 release credits 5,544 citations, a Journal Citation Indicator of 0.44 and a cited half-life of 10.7 years, with placings of 52 of 106 in biology and 129 of 191 in medicine.2025 年榜记录总被引 5544 次，期刊引文指标 0.44，被引半衰期 10.7 年，生物学类目 106 种里列第 52，医学研究与实验类目 191 种里列第 129。

Editors

• João Santana da Silva, of the Ribeirão Preto medical school at the University of São Paulo, is Editor-in-Chief and signs the final decision on every manuscript.主编为 João Santana da Silva，任职于圣保罗大学里贝朗普雷图医学院，每篇稿件的最终裁决由他签署。
• Ten editors work beneath him, among them Alessandra Carvalho Goulart and Itamar de Souza Santos of the university hospital, and Eduardo Magalhães Rego of the São Paulo medical school.主编之下设十位编辑，Alessandra Carvalho Goulart 与 Itamar de Souza Santos 来自大学医院，Eduardo Magalhães Rego 来自圣保罗医学院。
• The rest come from the state cancer institute and the Federal University of Ceará in Fortaleza, so the board is national rather than confined to a single campus.其余编辑来自州立癌症研究所与福塔莱萨的塞阿拉联邦大学，编委因此覆盖全国，并未局限于一所学校。
• Below the editors sit eight sections, one each for biochemistry and molecular biology, cell biology, clinical investigation, immunology, neuroscience and behaviour, pharmacology, physiology and biological pathogenic agents.编辑之下设八个分栏，生物化学与分子生物学居其一，病原生物与细胞生物学各占一栏，临床研究、免疫学与神经科学另有专人，药理学与生理学同样单列。
• A submission first passes a compliance check by the editorial assistant, then reaches the Editor-in-Chief, who either rejects it or hands it to a section editor.稿件先由编辑助理核对格式合规，再交到主编手中，主编决定退稿或转给分栏编辑。
• Review is double anonymous, so authors and referees stay unknown to each other, and preprints are handled with single anonymisation because author identities are already public.评审采用双向匿名，作者与审稿人互不知情，涉及预印本的稿件改用单向匿名，因为作者身份早已公开。
• Referees file opinions through ScholarOne, the section editor returns a verdict of minor or extensive revision, and revised versions go back to the same referees before a recommendation moves upward.审稿人在 ScholarOne 系统内提交意见，分栏编辑给出小幅修改或大修的结论，改稿回到原审稿人手中，之后才形成推荐意见。
• Similarity Check runs before review, and manuscripts with substantial overlap are rejected at that stage, a policy applied to original articles, reviews and short communications alike.查重在评审之前进行，重复率过高的稿件在这一步即被退回，该政策对原创论文、综述与短通讯一体适用。
• The board follows COPE guidance on authorship, consent, conflicts and misconduct, and retraction rests with the Editor-in-Chief after an inquiry that may call on outside experts.编委会依循 COPE 的出版伦理准则，署名、知情同意与利益冲突都在规约之列，撤稿由主编在调查之后决定，必要时征询外部专家。
• Reviews must be critical and synthetic rather than chronological, and four tests decide their fate, namely the author's record, the weight of the contribution, the quality of the synthesis and reader interest.综述须有批判性与综合判断，不能只按年代罗列文献，取舍依据作者在该领域的发表记录、贡献分量与综合质量，读者关注度另计。
• Abstracts stop at 250 words, keywords at six, running titles at 60 characters, and SI units with italicised gene and species names are enforced throughout.摘要不超过 250 词，关键词不超过 6 个，页眉短题不超过 60 个字符，全文强制使用国际单位制，基因名与物种名一律斜体。